Premium
Commentary on “Health economics and the value of therapy in Alzheimer's disease.” Drug treatment of Alzheimer's disease: The United Kingdom experience—National Institute for Health and Clinical Excellence guidance and guidelines for dementia
Author(s) -
Jones Roy
Publication year - 2007
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2007.04.386
Subject(s) - excellence , dementia , citation , value (mathematics) , disease , medicine , health care , library science , family medicine , gerontology , psychology , political science , law , computer science , pathology , machine learning
There has been widespread, international publicity conerning the availability of approved prescription medicines or the drug treatment of Alzheimer’s disease (AD) in the nited Kingdom, and the role of the National Institute for ealth and Clinical Excellence (NICE). This article will onsider the role of the NICE and the current status and vailability of drug treatment with acetylcholinesterase inibitors (ChEIs) and Memantine in England and Wales.